Industry Growth Insights published a new data on “Novel Antiviral Drugs Market”. The research report is titled “Novel Antiviral Drugs Market research by Types (Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators, Other), By Applications (Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics, Influenza Therapeutics, Other), By Players/Companies Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s, Gilead Sciences, Aurobindo Pharma, Cipla”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Novel Antiviral Drugs Market Research Report
By Type
Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators, Other
By Application
Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics, Influenza Therapeutics, Other
By Companies
Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s, Gilead Sciences, Aurobindo Pharma, Cipla
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
125
Number of Tables & Figures
88
Customization Available
Yes, the report can be customized as per your need.
Global Novel Antiviral Drugs Market Report Segments:
The global Novel Antiviral Drugs market is segmented on the basis of:
Types
Reverse Transcriptase Inhibitors, Protease Inhibitors, Fusion Inhibitors, Immune System Modulators, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis Therapeutics, HIV/AIDS Therapeutics, Herpes Therapeutics, Influenza Therapeutics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche Holding AG
- GlaxoSmithKline
- Bristol-Myers Squibb
- AbbVie
- Johnson & Johnson
- Merck & Co
- Novartis
- Dr Reddy’s
- Gilead Sciences
- Aurobindo Pharma
- Cipla
Highlights of The Novel Antiviral Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Fusion Inhibitors
- Immune System Modulators
- Other
- By Application:
- Hepatitis Therapeutics
- HIV/AIDS Therapeutics
- Herpes Therapeutics
- Influenza Therapeutics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Novel Antiviral Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
New antiviral drugs are those that have not been used before to treat viruses.
Some of the major companies in the novel antiviral drugs market are Roche Holding AG, GlaxoSmithKline, Bristol-Myers Squibb, AbbVie, Johnson & Johnson, Merck & Co, Novartis, Dr Reddy’s, Gilead Sciences, Aurobindo Pharma, Cipla.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Novel Antiviral Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Novel Antiviral Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Novel Antiviral Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Novel Antiviral Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Novel Antiviral Drugs Market Size & Forecast, 2018-2028
4.5.1 Novel Antiviral Drugs Market Size and Y-o-Y Growth
4.5.2 Novel Antiviral Drugs Market Absolute $ Opportunity
Chapter 5 Global Novel Antiviral Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Novel Antiviral Drugs Market Size Forecast by Type
5.2.1 Reverse Transcriptase Inhibitors
5.2.2 Protease Inhibitors
5.2.3 Fusion Inhibitors
5.2.4 Immune System Modulators
5.2.5 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Novel Antiviral Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Novel Antiviral Drugs Market Size Forecast by Applications
6.2.1 Hepatitis Therapeutics
6.2.2 HIV/AIDS Therapeutics
6.2.3 Herpes Therapeutics
6.2.4 Influenza Therapeutics
6.2.5 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Novel Antiviral Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Novel Antiviral Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Novel Antiviral Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Novel Antiviral Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Novel Antiviral Drugs Market Size Forecast by Type
9.6.1 Reverse Transcriptase Inhibitors
9.6.2 Protease Inhibitors
9.6.3 Fusion Inhibitors
9.6.4 Immune System Modulators
9.6.5 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Novel Antiviral Drugs Market Size Forecast by Applications
9.10.1 Hepatitis Therapeutics
9.10.2 HIV/AIDS Therapeutics
9.10.3 Herpes Therapeutics
9.10.4 Influenza Therapeutics
9.10.5 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Novel Antiviral Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Novel Antiviral Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Novel Antiviral Drugs Market Size Forecast by Type
10.6.1 Reverse Transcriptase Inhibitors
10.6.2 Protease Inhibitors
10.6.3 Fusion Inhibitors
10.6.4 Immune System Modulators
10.6.5 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Novel Antiviral Drugs Market Size Forecast by Applications
10.10.1 Hepatitis Therapeutics
10.10.2 HIV/AIDS Therapeutics
10.10.3 Herpes Therapeutics
10.10.4 Influenza Therapeutics
10.10.5 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Novel Antiviral Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Novel Antiviral Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Novel Antiviral Drugs Market Size Forecast by Type
11.6.1 Reverse Transcriptase Inhibitors
11.6.2 Protease Inhibitors
11.6.3 Fusion Inhibitors
11.6.4 Immune System Modulators
11.6.5 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Novel Antiviral Drugs Market Size Forecast by Applications
11.10.1 Hepatitis Therapeutics
11.10.2 HIV/AIDS Therapeutics
11.10.3 Herpes Therapeutics
11.10.4 Influenza Therapeutics
11.10.5 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Novel Antiviral Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Novel Antiviral Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Novel Antiviral Drugs Market Size Forecast by Type
12.6.1 Reverse Transcriptase Inhibitors
12.6.2 Protease Inhibitors
12.6.3 Fusion Inhibitors
12.6.4 Immune System Modulators
12.6.5 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Novel Antiviral Drugs Market Size Forecast by Applications
12.10.1 Hepatitis Therapeutics
12.10.2 HIV/AIDS Therapeutics
12.10.3 Herpes Therapeutics
12.10.4 Influenza Therapeutics
12.10.5 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Novel Antiviral Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Novel Antiviral Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Novel Antiviral Drugs Market Size Forecast by Type
13.6.1 Reverse Transcriptase Inhibitors
13.6.2 Protease Inhibitors
13.6.3 Fusion Inhibitors
13.6.4 Immune System Modulators
13.6.5 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Novel Antiviral Drugs Market Size Forecast by Applications
13.10.1 Hepatitis Therapeutics
13.10.2 HIV/AIDS Therapeutics
13.10.3 Herpes Therapeutics
13.10.4 Influenza Therapeutics
13.10.5 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Novel Antiviral Drugs Market: Competitive Dashboard
14.2 Global Novel Antiviral Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche Holding AG
14.3.2 GlaxoSmithKline
14.3.3 Bristol-Myers Squibb
14.3.4 AbbVie
14.3.5 Johnson & Johnson
14.3.6 Merck & Co
14.3.7 Novartis
14.3.8 Dr Reddy’s
14.3.9 Gilead Sciences
14.3.10 Aurobindo Pharma
14.3.11 Cipla
